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DIRECT COSTS OF PNEUMONIA IN THE UNITED STATES: AN ANALYSIS OF 2008
MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA
Parkv H, Rascati KL
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To estimate annual health care utilization and costs of pneumonia
across age cohorts in the United State (US) from an all-payer perspective.
METHODS: A retrospective cross-sectional study was conducted using the 2008
Medical Expenditure Panel Survey (MEPS) database, a nationally representative
annual survey of the civilian non-institutionalized population of the US. Pneu-
monia patients were identified as those with a Clinical Classification Code for
pneumonia (code with 122). Resources used and expenditures incurred by pa-
tients with pneumonia that were directly attributable to pneumonia treatment
(physician office visits, emergency room visits, outpatients visits, inpatient vis-
its, other medical visits, and medications) were estimated. Health care costs per
year per person (PYPP) were assessed across five age cohorts (5, 5-18, 18-50,
50-64, and 65 years old) and reported in 2008 US dollars. RESULTS: A total of
297 patients (representing 3.1 million persons) reported using medical re-
sources or incurring expenditures due to pneumonia. Direct medical costs at-
tributable to pneumonia were estimated at $2,763 (standard error [SE] 344) per
patient. Approximately 86% ($2,394) of this estimate was generated by inpatient
hospitalizations for pneumonia, which were experienced by 26.9% of pneumo-
nia patients, with an average of 0.31 admissions per patient. Physician office
visits and home health visits were the next largest categories of expenditure,
contributing $153 (5.5%) and $113 (4.1%), respectively. By age cohort, mean at-
tributable costs PYPP for patients 5 (n47), 5-18 (n38), 18-50 (n41), 50-
64 (n108), and 65 years old (n63) were $2,166 (1043), $579 (119), $1,747
($888), $2,983 (556), and $4,201 (553), respectively (p 0.05). CONCLUSIONS:
This study provides an overview of clinical and economic burden of pneumonia
in the US. Pneumonia-attributable expenditures were considerable, strongly
driven by high inpatient hospitalization cost. In addition, patients aged  65
years had highest expenditures of pneumonia among all age cohort.
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TRENDS IN UK SMOKING CESSATION PRESCRIPTION EXPENDITURE OVER
TIME - A THIN DATABASE STUDY
Blak BT, Lee J, Dungarwalla M
Cegedim Strategic Data Medical Research Ltd, London, UK
OBJECTIVES: In the UK, smoking cessation prescriptions (SCPs) include bupro-
pion, nicotine replacement therapy (NRT) and varenicline, where NRT and bu-
propion were available around 2000 and varenicline in 2006, with NRT being
relatively less expensive. This study evaluates the trends in SCP expenditure
from the national payer perspective. METHODS: From patients 18 years, an-
nual SCPs were obtained between January 1, 2000 - December 31, 2009 from The
Health Improvement Network (THIN) database, which holds anonymised longi-
tudinal UK primary care data from 500 practices. Drug prices came from the
British National Formulary March 2010 to estimate real growth in expenditure.
Expenditure trends were disaggregated by prescription frequency; treatment
prevalence, defined as the number of patients receiving a SCP in THIN; SCPs per
patient treated; and average drug expenditure per SCP. Sensitivity of 5% was
applied towards expenditure. RESULTS: Total number of SCPs was 9,706 in 2000
and estimated 131,466 in 2009. SCP expenditure were estimated at 7,416,741£
(range:7,045,904-£;7,787,578£) in 2000 (2010 £ values) and 77,904,026£ in 2009
(range:74,008,825-£; 81,799,228£) reflecting a 950.4% real rate of increase. Bupro-
pion prescription frequency was 70.8% in 2000 decreasing to 2.2% in 2009, NRT
frequency was 29.2% in 2000 peaking at 94.4% in 2006 and declining to 65.1% in
2009, and varenicline frequency was 16.8% in 2007 increasing to 32.8% in 2009.
Treatment prevalence rose from 0.3% in 2000 to 2.0% in 2009, while the average
annual SCPs per patient treated increased from 1.5 to 3.0. The average SCP
expenditure per SCP decreased to 22.2£ in 2006, however increased to 25.8£ in
2009. CONCLUSIONS: The expenditure increase reflects increase in treatment
prevalence and average annual SCPs per patient treated. Furthermore, the in-
troduction of varenicline may have impacted recent expenditures as the aver-
age SCP expenditure per SCP increased at varenicline introduction, suggesting a
product shift towards more expensive SCPs.
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ADHERENCE TO CURRENT GUIDELINES FOR CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD) IN SUBJECTS TREATED WITH COMBINATION
OF LONG-ACTING 2-AGONIST (LABA), LONG-ACTING MUSCARINIC
ANTAGONIST (LAMA) OR INHALED CORTICOSTEROIDS (ICS)
Asche C1, Leader S2, Plauschinat C3, Raparla S4, Ye X4, Yan M4, Young D4
1University of Illinois College of Medicine, Peoria, IL, USA, 2Novartis, East Hanover, NJ, USA,
3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4University of Utah College of
Pharmacy, Salt Lake City, UT, USA
OBJECTIVES:To estimate the potential cost savings and reduction in exacerbations
by following guideline recommendations in subjects being treated for COPD with
the combination of LABA, LAMA or ICS. METHODS: Subjects were identified with a
diagnosis for COPD using ICD-9 codes between January 1, 2004 to December 31,
2007. The index date was based on first prescription of a LAMALABA,
LAMALABA/ICS, or LABAICS. Based on pulmonary function test (PFT) data
within 30 days of the index date, subjects were classified as adhering or non-
adhering to guidelines. Chi-square and t-test were conducted to determine the
differences among cohorts. RESULTS: A total of 365 subjects were identified as
adhering or non-adherent to guidelines based on their PFT data. Oxygen were
significantly higher in LAMA plus LABA/ICS and lower in LABA/ICS as compared to
LAMA plus LABA cohort (p0.05). Also, number of office visits and hospital admis-
sions were significantly higher in LAMA plus LABA/ICS compared to LAMA plus
LABA cohort. The mean number of prescriptions for antibiotics and prednisone
was higher in LAMA plus LABA/ICS cohort. The highest mean number of baseline
exacerbations was observed in LAMA plus LABA/ICS group (12.9) with 6.06 in LABA
plus ICS group and 7.76 in LAMA plus LABA group. 31% of the subgroup received
COPD medications consistent with guidelines was associated with cost savings of
$5,889 for LAMA plus LABA, $3,330 for LABAICS, and $10,217 for LAMA plus LABA/
ICS cohorts. The LAMA plus LABA (1.3 vs. 2.9) LABA plus ICS (2.78 vs. 3.57), and
LAMA plus LABA/ICS (-0.82 vs. 3.62) cohorts had lower mean change in exacerba-
tions in adhering group versus non-adhering group. CONCLUSIONS: Adherence to
current GOLD guidelines is associated with lower costs and fewer exacerbations in
subjects with moderate to severe COPD for LAMA plus LABA, LABA plus ICS and
LAMA plus LABA/ICS groups. AbstractsAbstracts
PRS29 EVALUATION OF STABLE COPD MEDICATION COSTS IN UKRAINE BASED
ON GPS’ PRESCRIPTIONS HABITS SURVEY RESULTS
HolovatyukI1Zalis’kaO2TolubaievV2
1O.O. Bohomolets National Medical University, Kyiv, Ukraine, 2Danylo Halytsky Lviv National
Medical University, Lviv, Ukraine
OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a major cause of
chronic morbidity and mortality throughout the world. There was not any reliable
information about its prevalence, morbidity and mortality in Ukraine until 2009.
METHODS: We analyzed the data about COPD from the first report of Ukrainian
Center of Medical Statistics. Than we calculated, the number of COPD cases needed
the basis in 2009 and the approximate costs for COPD basis therapy based on data
from the survey of Ukrainian GP’s prescription habits in treatment of stable COPD.
RESULTS: According to the Ukrainian Center’s of Medical Statistics data in 2009
prevalence of COPD in Ukraine amounted to 998.7 per 100,000 (377,267 persons),
morbidity – 79.2 per 100,000 (29,928 persons), mortality – 29.5 per 100,000 (11,121
persons). The number of persons with COPD needed the basis were 336,218 (total
number of cases excluding new patients and deaths). According to our survey of
Ukrainian GP’s prescription habits for stable COPD basis 56.8% of COPD patients
were given by fenoterol/ipratropium with annual costs per patient €120, 10.2% -
tiotropium with €606.2 annually, 9.1% - fenoterol with €103.3, 7.9% - salbutamol
with €27.5, 7.2% - fluticazone/salmeterol with €185, 6.8% - theophylline with €48.7,
2% - budesonide/formoterol €187.5 per patient annually. Therefore, in 2009 in
Ukraine the expenditures for basis treatment of 336,218 COPD patients’ with
fenoterol/ipratropium, tiotropium, fenoterol, salbutamol, fluticazone/salmet-
erol, theophylline budesonide/formoterol were €22,916,618.88, €20,789,165.86,
€3,160,550.07, €730,433.61, €4,478,423.76, €1,113,419.53, €1,260,817.50, respec-
tively. Moreover, the total basis medications costs in 2009 could be
€54,449,429.20 (€161.94 per patient). CONCLUSIONS: The study results showed
that basis medication costs per COPD patient in Ukraine could correspond with
costs in several EU countries. And we need to provide comparative cost studies for
medications reimbursement-system creation.
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IDENTIFYING THE PATIENT POPULATION WHERE TREATMENT OF SEVERE
ALLERGIC ASTHMA WITH OMALIZUMAB (XOLAIR®) EXHIBITS OPTIMAL COST-
EFFECTIVENESS IN AUSTRALIA
Tilden D1, Cottrell S1, Tocchini L1, Frenzel C2, Bonney MA2
1THEMA Consulting Pty Ltd, Pyrmont, NSW, Australia, 2Novartis Pharmaceuticals Australia,
North Ryde, NSW, Australia
OBJECTIVES: In Australia omalizumab (OM) is indicated for moderate-to-severe
allergic asthma. Two randomised controlled trials conducted in patients with se-
vere asthma compared optimised asthma therapy (OAT) (includes maximal in-
haled therapy) versus OMOAT. This analysis was to identify a patient subgroup in
which clinical need, comparative costs and effectiveness of OM is greatest.
METHODS: A Markov model incorporating local treatment algorithms and data
from the trials was developed. Patient subgroups were defined according to base-
line use of maintenance oral corticosteroids (MOCS), Asthma Control Question-
naire (ACQ-5) and Asthma Quality-of-Life Questionnaire (AQLQ) scores, FEV&rtf-
inf-start;1&rtf-inf-end;, exacerbation history and combinations of these. Costs and
effectiveness of OMOAT were compared with OAT alone. OM was continued only
while patients exhibited treatment response. Various definitions of response were
examined to optimise continuation criteria. Model parameters included: clinically
significant asthma exacerbations; hospital admissions; emergency visits; change
in MOCS dose; impact of MOCS on risk of certain chronic conditions; ACQ-5, AQLQ
and EQ5D utility index scores. The model estimated numbers of clinically signifi-
cant severe asthma exacerbations, deaths, life-years and QALYs gained due to OM.
RESULTS: OMOAT showed optimal cost-effectiveness in patients uncontrolled
on or intolerant to MOCS, with a baseline ACQ-5 2.0 or AQLQ 5.0. Response for
OM continuation was optimally defined as a reduction in ACQ-5 0.5 or 25%
reduction in MOCS dose without deterioration in ACQ-5. These patients benefitted
most from OM because they had severe disease, and were able to reduce exacer-
bations and MOCS dose and associated MOCS risks. The low baseline AQLQ score
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meant these patients had greatest propensity for quality-of-life improvements and
QALY gains, resulting in the public subsidy recommendation in this patient sub-
group by the PBAC in Australia. CONCLUSIONS: Patients using MOCS with a base-
line ACQ-5 2.0 or AQLQ 5.0 are those in whom OM shows optimal cost-effec-
tiveness in the Australian healthcare environment.
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ECONOMIC EVALUATION OF INDACATEROL IN CHRONIC OBSTRUCTIVE
PULMONARY DISEASE (COPD) FROM THE PUBLIC PAYER PERSPECTIVE IN
BRAZIL
Suzuki C1, Silva NL2
1Novartis Biociências SA, São Paulo, Brazil, 2Novartis Biociências SA, Sao Paulo, Brazil
OBJECTIVES: To assess the cost-effectiveness of indacaterol in comparison to
tiotropium and formoterol from Brazilian public healthcare system perspective.
METHODS: A Markov model was designed to project costs and outcomes associ-
ated with disease progression of patients with COPD over 3-years time horizon. The
model health states are divided by severity of COPD (mild, moderate, severe and
very severe) with each of these states divided into three states: no exacerbation,
non-severe and severe exacerbations. The target population consists of patients
with moderate or severe COPD, and the health states for mild and very severe COPD
are included to account for those who improve in first cycle to the mild state and
those who progress to very severe state over time. Efficacy data and exacerbation
rates were obtained from the pivotal trials. Mortality data for COPD-specific states
are based on study by Rutten-van Mölken et al. COPD related medical resource
utilization patterns were assessed through clinical experts’ panel. Unit costs were
extracted from Brazilian official lists. Outcomes are expressed as life years gained
(LYG). One-way sensitivity analysis was performed. Annual discount rate of 5% was
applied both to costs and outcomes. RESULTS: Base case analysis estimated incre-
mental LYG for indacaterol of 0.010 vs. formoterol and 0.006 vs. tiotropium. Inda-
caterol was cost-saving as compared to tiotropium (incremental cost of -2,667BRL).
Comparing to formoterol, the projected ICER was 25,458BRL per LYG. The variables
that most influenced the results were time horizon, mortality rates and baseline
population.CONCLUSIONS: Indacaterol is a valuable alternative for COPD patients,
being a cost-saving treatment vs. tiotropium with incremental clinical benefits and
lower costs. Versus formoterol, indacaterol has incremental benefit, at a reason-
able incremental cost.
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COST-EFFECTIVENESS OF OMALIZUMAB IN SEVERE UNCONTROLLED ALLERGIC
ASTHMA USING RCT AND REAL-WORLD EVIDENCE IN THE DUTCH SETTING
Stern S1, van Nooten F2, Groot M3, Brown R1
1United BioSource Corporation, Bethesda, MD, USA, 2United BioSource Corporation, London, UK,
3Novartis Pharma B.V., Arnhem, The Netherlands
OBJECTIVES: The objective of this analysis was to compare results of two cost-
effectiveness analyses for omalizumab added to standard therapy in severe allergic
asthma patients using an RCT (INNOVATE) compared to a real-world, prospective
observational study (EXPERIENCE). METHODS: A Markov model was developed to
examine the cost-effectiveness of add-on omalizumab versus standard care from
the perspective of the Dutch health care system over a patient’s lifetime. Efficacy
data for clinically significant (CS) exacerbations and resource use (hospital admis-
sions, unscheduled physician visits and emergency visits) were derived from IN-
NOVATE or Dutch patients enrolled in EXPERIENCE. Data from each were projected
to lifetime with discounted future costs (4%) and outcomes (1.5%). RESULTS: For
the EXPERIENCE study, the modelled direct medical costs for patients on standard
therapy were €77,615, of which 75% was for exacerbation control versus €133,475
for standard therapy  omalizumab, of which 38% was for exacerbation control.
Patients on omalizumab had more QALYs than those on standard therapy alone,
12.05 versus 10.47. The resulting ICER was €35,257/QALY for the EXPERIENCE study.
The INNOVATE costs were lower in both treatment arms: €22,499 for standard
therapy and €58,666 for standard therapy  omalizumab. Costs were lower due to
lower rate of CS exacerbations in the RCT where patients had been under best
possible control at trial entry. QALYs were similar to the EXPERIENCE study 12.05
and 10.91, respectively; resulting in €31,802/QALY. CONCLUSIONS: Decision-mak-
ers are often presented with cost-effectiveness evidence from RCTs although they
prefer to base decisions on real-world data are preferred. This study is one the first
to include both in a re-evaluation dossier. It showed differences in patient charac-
teristics (exacerbation rates and resource use) between the RCT and observational
study. However it confirmed the value of omalizumab with similar ICERs, indicat-
ing that omalizumab is cost effective in both settings.
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A COST-EFFECTIVENESS ANALYSIS OF VARENICLINE VERSUS BUPROPRION
AND NICOTINE REPLACEMENT THERAPY IN GREECE
Athanasakis K1, Igoumenidis M1, Karampli E1, Vitsou E2, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2Pfizer Hellas, Athens, Greece
OBJECTIVES: To evaluate the cost-effectiveness of varenicline compared to bupro-
pion and nicotine-replacement therapy (NRT) from a third-party payer (Social In-
surance Fund) perspective in Greece. METHODS: The Benefits of Smoking Cessa-
tion on Outcomes (BENESCO) Markov model was applied to calculate the long-term
health and economic benefits of smoking cessation, simulating the incidence and
outcomes of smoking-related morbidities to a hypothetical cohort of patients (age-
and gender-representative of the Greek population) making a single quit attempt.
Demographic, epidemiological, treatment efficacy and economic inputs for the
modelled cohort were obtained from the literature and publicly available data from
public healthcare databases. The model calculated costs and outcomes for a life-
time perspective, discounted at a 3% discount rate and reported in year 2011 fees
and prices. Extensive probabilistic sensitivity analysis was performed to test the
robustness of the results. RESULTS: The cohort consisted of 819,709 current smok-
ers making a quit attempt. The respective 1year continuous abstinence rates were
22.5%, 15.5% and 15.4% for quitters under varenicline, NRT and bupropion. For a
lifetime horizon, varenicline prevented in total 7652 and 7609 additional cases of
smoking-related disease (coronary heart disease, stroke, lung cancer, chronic ob-
structive pulmonary disease) versus NRT and bupropion, respectively. Moreover,
varenicline led to a gain of 21,219 QALYs (16,955 life years) and 21,099 QALYs (16,859
life years) for the cohort, compared to NRT and bupropion. Taking direct costs into
account, varenicline produced cost-savings against both comparators for the life-
time as well as for shorter (20year) timeframes of analysis. The probabilistic sen-
sitivity analysis corroborated the study outcomes. CONCLUSIONS: Taking into ac-
count the Social Security perspective in Greece, varenicline was a dominant
smoking cessation strategy compared to NRT and bupropion, reducing both treat-
ment costs and smoking-related morbidity.
PRS34
COST-EFFECTIVENESS OF ROFLUMILAST (DAXAS®) IN THE TREATMENT OF
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN SPAIN
Lindner L1, Camins de Valdenebro L2, Aparicio Martinez J2
1IMS Health, Barcelona, Cataluña, Spain, 2Nycomed Pharma S.A., Madrid, Madrid, Spain
OBJECTIVES: To estimate the cost-effectiveness of roflumilast (Daxas®) versus the
most prescribed drug combination in Spain in the treatment of adult patients with
severe chronic obstructive pulmonary disease (COPD) with a history of frequent
exacerbations. METHODS: A Markov model was constructed to estimate the life
time cost-effectiveness of roflumilast plus a long acting muscarinic antagonist
(roflumilast  LAMA) versus the combination of LAMA with a long-acting beta
agonist plus and an inhaled corticosteroid (LAMALABA/ICS). Outcomes were ex-
pressed as the incremental cost per exacerbation avoided from the Spanish Na-
tional Health System perspective using a life-time horizon (30 years). Other health
outcomes in the model include quality-adjusted life year (QALY) gained and life
years (LY) gained. The key inputs to the model are based on roflumilast pivotal
clinical trials and published epidemiological and population data. Uncertainty in
the model’s parameters was examined by sensitivity analysis. RESULTS: The re-
sults of the economic analysis have demonstrated that over the lifetime of the
treatment of patients with severe COPD and associated chronic bronchitis with a
history of frequent exacerbations, the roflumilast LAMA strategy will cost 3468 €
less than using LAMA  LABA/ICS. Over a lifetime a patient treated with a roflu-
milast LAMA is estimated to have 1.23 exacerbations less and 0.129 more QALYs
that a patient treated with LAMA LABA/ICS. Therefore, the roflumilast treatment
arm appears to be the dominating option. The sensitivity analyses showed that the
variable that has the most impact on the ICER results is the relative risk of
exacerbations. CONCLUSIONS: Roflumilast  LAMA offers a cost-effective option
for the maintenance treatment of severe COPD associated with chronic bronchitis
in patients with a history of frequent exacerbations compared with LAMA LABA/
ICS.
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ECONOMIC EVALUATION OF INDACATEROL VERSUS TIOTROPIUM OR
FORMOTEROL FOR PATIENTS WITH MODERATE TO SEVERE COPD IN GREECE
Geitona M1, Hatzikou M2, Bania E2
1University of Peloponnese, Athens, Greece, 2Novartis Hellas, Metamorfosis, Greece
OBJECTIVES: Evaluate the cost-effectiveness of indacaterol (Onbrez Breezhaler,
150g & 300g) against tiotropium (Spiriva, 18g) or formoterol (Foradil, 12g twice
daily) respectively. METHODS: A Markov model was developed describing each
COPD disease severity stage based on pre-bronchodilator FEV1 measurements re-
ported in the indacaterol clinical trials (INVOLVE & INHANCE). The outcomes as-
sessment criteria were Quality-Adjusted Life-Years (QALYs), Life Years Gained
(LYG) and exacerbation rates. A 3-year time horizon was used for the cost-utility
analysis (CUA) and a lifetime (25 year) time horizon was used for the cost-effec-
tiveness analysis (CEA). Discount rates of 3.5% were set for both costs and out-
comes and univariate sensitivity analyses were conducted. Resource utilization
was based on Greek published data and relevant costs on official NHS prices.
RESULTS: The mean number of QALYs per patient in the three-year CUA was 2.152
in the indacaterol 150g arm and 2.144 in the tiotropium arm, resulting in 0.0078
QALYs in favor of indacaterol; the total costs per patient were €9,717 in the inda-
caterol arm and €9,853 in the tiotropium arm, resulting in €136 savings in favor of
indacaterol, gaining the dominant position (lower total costs, better outcomes).
The CEA over the lifetime is similarly dominant with 10.213 LYG for indacaterol and
10.119 LYG for tiotropium and a lower cost per patient for indacaterol. The CUA
comparing indacaterol 300g and formoterol also resulted in indacaterol dominat-
ing formoterol with an incremental QALY of 0.017 (2.149 and 2.132 respectively) and
a cost saving of €48.23 compared to formoterol over 3 years. Similarly, indacaterol
dominates the CEA over a life time. Regarding exacerbation rates, although very
similar outcomes appeared among treatments, COPD treatment was less costly
with indacaterol against all other comparators. CONCLUSIONS: For patients with
moderate to severe COPD, indacaterol represents a cost-effective treatment and is
potentially cost saving for the Greek NHS.
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THE COST-EFFECTIVENESS OF STEP DOWN FROM HIGH DOSE ICS/LABA
COMBINATION THERAPY IN ASTHMA IN THE UK SETTING
Paggiaro P1, Buseghin G2, Nicolini G2, Patel S2, Iannazzo S3, Zaniolo O3, Papi A4
1University of Pisa, Pisa, Italy, 2Chiesi Farmaceutici, Parma, Italy, 3AdRes HE&OR, Turin, Italy,
4University of Ferrara, Ferrara, Italy
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